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Abstract
Delayed recurrences, common in breast cancer, are well explained
by the concept of tumour dormancy. Numerous publications
describe clinical times to disease recurrence or death, using
mathematical approaches to infer mechanisms responsible for
delayed recurrences. However, most of the clinical literature
discussing tumour dormancy uses data from over a half century
ago and much has since changed. This review explores how
current breast cancer treatment could change our understanding
of the biology of breast cancer tumour dormancy, and summarizes
relevant experimental models to date. Current knowledge gaps are
highlighted and potential areas of future research are identified.
Introduction
Breast cancer remains the leading cancer diagnosis among
women in the western world. With ever-improving chemo-
therapeutic, radiation and hormonal treatments, clinicians
have seen an improvement in overall survival, leading to
increasing numbers of patients living with breast cancer [1].
Due in part to these advances, breast cancer, and in
particular early breast cancer, appears to behave increasingly
akin to a chronic disease [2]. Patients who have distant or
regional metastasis at the time of diagnosis have poor clinical
outcomes in terms of early distant disease and subsequent
death from breast cancer. However, scientists and clinicians
alike have become intrigued with the finding that many
patients who are diagnosed at an early stage, with small
tumours and no evidence of regional lymph node metastases,
can have a high level of recurrence when followed for greater
than 10 to 15 years, in excess of 25% to 30% [2,3]. In such
patients who are estrogen receptor positive, for example,
more patients recur after completing five years of hormonal
therapy, such as tamoxifen, than they do in the first five years
[1]. These findings suggest that perhaps our understanding
of the biology of breast cancer recurrence and the implica-
tions for tumour dormancy research should be reviewed in
the setting of current clinical treatments for breast cancer,
and the biology of tumour response to these treatments.
Clinical dormancy in breast cancer
When using the term ‘tumour dormancy’ in this review, we are
referring to breast cancers that become clinically evident
following a prolonged disease-free interval. Although there is
no strict definition to the time interval between initial treat-
ment and disease recurrence, many publications have noted
disease-free intervals in excess of five to six years. In the
literature published to date in the field of tumour dormancy in
breast cancer, two prominent authors have contributed
significantly to the field: Demicheli [4-7] and Karrison [8,9].
Demicheli and colleagues [7] have studied the timeline of
disease recurrence based on a retrospective database
(initiated in the 1940s in Italy) of 1,173 patients treated by the
accepted treatments of that era, radical or modified radical
mastectomy (Figure 1). Their findings of disease recurrences
up to 20 years after diagnosis were felt to support the concept
of tumour dormancy by breast cancer cells. It is important to
note that only a minority of those patients received any
adjuvant chemotherapy and/or radiation, and there was no
mention of adjuvant hormonal therapy, which would likely not
have been considered standard of care at that time. Demicheli
and colleagues [10] subsequently presented further data on
these patients, comparing chemotherapy-treated patients
versus none and determined that chemotherapy was
beneficial in reducing early recurrences but not late
recurrences. Karrison and colleagues [8] also retrospectively
studied 1,547 patients diagnosed between 1945 and 1987.
Demicheli and colleagues demonstrated that plotting the
hazard rate (or conditional probability of outcome) from time of
surgery to death revealed a peak incidence of death at 1 to
2 years and again at 5 years (60 months) [7,9-11]. These
studies have led to speculation that this peak in death at five
years likely represents the awakening of dormant tumour cells
unaffected by adjuvant regional or systemic treatment [6-11].
In Figure 1, use of cytotoxic chemotherapy (cyclophospha-
mide, methotrexate and fluorouracil (CMF)) post-mastectomy
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was shown to result in a dampening of the first, early peak of
recurrences, with little effect on later recurrences, suggesting
that this chemotherapy, while improving survival for the group,
was having minimal effect on the development of late
recurrences, seen to peak at five years post-treatment.
The theory of tumour dormancy, rather than steady re-growth
of remaining cancer in these patients, is supported by growth
kinetic theory utilizing mathematical models to estimate
residual tumour cell doubling times [5], because recurrences
were found to develop considerably later than would be
expected based on growth kinetics alone. Additionally, the
rate of tumour growth from clinically undetectable to clinically
evident recurrence further supports this theory [4]. This
theory is consistent with multiple clinical datasets, but the
mechanisms responsible remain poorly elucidated.
Although delayed recurrences and graphical representation
to suggest a peak in recurrence several years after initial
treatments is of great clinical and scientific interest, there is
no doubt that the patients included in the above studies were
treated by what would be considered now to be substandard
therapy. Additionally, findings obtained from early studies
initiated in the 1940s are difficult to apply to current patient
populations due to changes in overall life expectancies. Thus,
it will be of great interest to learn if current therapies are able
to reduce late-occurring recurrences, in addition to improving
overall and disease-specific survival.
Evaluations to date of current randomized clinical trials data
with long term follow-up have consistently demonstrated a
smooth cumulative incidence curve for disease recurrence
(cumulative frequency of recurrence with each subsequent
time point) with a gradual decline in slope after 10 years
[1,3,12-14]. This differs from the double recurrence peaks
proposed by Demicheli (Figure 1), where the time to
recurrence is plotted as a hazard function (incidence of
recurrence for each time point). If a peak in recurrence at the
five year mark had remained, as was seen by Demicheli and
Karrison, one would have expected to see an increase in the
slope of cumulative incidence over that time in the more
recent studies described above. The majority of current
publications of international trials display their results as
cumulative incidence functions rather than hazard rates
(otherwise termed conditional probability plots), subdivided
by various treatments (chemotherapy with or without
tamoxifen, mastectomy with or without radiation, aromatase
inhibitor versus not, high risk phenotype versus low risk, and
so on; for examples, see Figure 2 in [14], Figure 4 in [3] and
Figure 8 in [1]). Thus, even when therapies are effective
overall, steady increases in numbers of late recurrences are
seen for both early and late stage tumours. Our intent in
highlighting this difference is simply to demonstrate that the
peaks in cancer recurrences demonstrated by Demicheli are
not readily seen in long-term follow-up data in patients treated
with current treatment regimes. As such, our understanding
of tumour dormancy should be updated in light of current
treatment methods (radiation, hormonal therapy and tumour
targeted antibody treatments), which are likely influencing
tumour dormancy in a different way now compared to patients
in the era of Demicheli’s database, as shown by vast differences
in breast cancer mortality rates and recurrence patterns.
Currently in North America and Europe, the vast majority of
breast cancers are treated by lumpectomy, also referred to as
segmental mastectomy, with adjuvant radiation. For patients
considered by phenotypic tumour markers to be at high risk
of recurrence (node positive, lymphatic or vascular invasion
present, tumour size and grade, pre-menopausal status,
Her2/neu over-expression), systemic chemotherapy is
offered. Standard North American and European chemo-
therapy regimens are anthracycline-based, often with the
addition of a taxane [1]. Regimens are intravenous q3 weekly
for six to eight cycles, typically lasting almost six months.
Patients who are Her2/neu over-expressers are then offered
intravenous trastuzumab (Herceptin®; Her2-targeted mono-
clonal antibody therapy) for one year. Concurrently, they are
also offered 5,000 Gy of tangential radiation over 25 to 30
fractions [12]. Patients with estrogen and/or progesterone
receptor-positive tumours are additionally offered five to ten
years of hormonal therapy (estrogen receptor blockade or
aromatase inhibition) [13].
Overall, these therapies are improving patient disease-
specific and overall survival [12]. Nonetheless, late
recurrences can and do occur in patients treated with various
current therapies. This fact emphasizes the concept that
Figure 1
Comparison of the hazard function for development of distant
metastases among axillary lymph node positive breast cancer patients
treated with mastectomy without (upper curve) or with (lower curve)
adjuvant chemotherapy (cyclophosphamide, methotrexate and
fluorouracil (CMF)). Note that the x-axis is displayed in six month units.
Reprinted from [7], with permission from Elsevier.Page 3 of 7
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current (as well as past) therapies may be ineffective in
reaching or killing some subset of cancer cells, such as those
that are dormant, which may be responsible for late
recurrences. This concept is consistent with the theory that
some disseminated cancer cells are resistant to various
treatments, especially those therapies that target actively
dividing cells [15-17]. As noted below, this idea is further
supported by results from experimental models in which
dormancy can exist in two states: solitary dormant cells
[17-21] and active but pre-angiogenic micrometastases [22].
It has been shown that solitary, dormant cancer cells can
exist in a quiescent state, and can be spared by cytotoxic
chemotherapy that is effective against the same cells when
they are in an actively dividing state [15]. It will thus be of
great interest to follow patients being treated with current
treatment protocols to assess how effective they will be at
preventing late recurrences.
Insights into tumour dormancy from
pre-clinical models
To better understand how changes in breast cancer
treatment may affect tumour recurrence, an improved under-
standing of the source of recurrent cancer is required.
Assuming successful removal of the primary tumour,
metastatic recurrence is the result of tumours formed by
malignant cells that have spread from the primary tumour to a
secondary tissue. While often lethal, metastasis, the process
by which cancer cells spread, is an extremely inefficient
process and most cells shed from a primary tumour behave in
a non-metastatic fashion [17-18,21,23-25]. For a cancer cell
to successfully form a metastatic tumour, it must detach from
the primary tumour, intravasate into a blood or lymphatic
vessel, survive transit within the vasculature, arrest in a
secondary site, extravasate into the secondary tissue and
commence and continue growth in this new micro-
environment [25]. As failure at any of these numerous steps
in the process will result in failure of the cell to form a
clinically relevant metastatic tumour, it is perhaps not
surprising that metastasis is an extremely inefficient process.
Indeed, in experimental models of hematogenous metastasis
only a very small proportion (for example, 0.02% or less,
depending on the model) of cells successfully forms large
vascularized metastases [17] despite more than 80% of cells
successfully extravasating from the vasculature [18,26].
Similar metastatic inefficiency and failure of most circulating
tumour cells to form metastases has also been reported in
human cancer [27].
Experimental metastasis models have also revealed that a
variable, but often significant, proportion of cancer cells that
are delivered to a secondary organ can remain as solitary
dormant cells for prolonged periods [18,19,21,24].
Metastatic inefficiency then can be attributed to two main
causes, cell death and dormancy (Figure 2). While cells that
undergo cell death, due to apoptosis or other mechanisms,
are of no further clinical relevance, cells or micrometastases
that remain dormant are a possible source of later tumour
formation and, therefore, recurrence. This model is entirely
consistent with the clinical model of dormancy proposed by
Demicheli (see Figure 4 in [7]).
Following extravasation into a secondary organ, metastatic
cells can undergo one of three possible fates (Figure 2): they
can undergo cell death (apoptosis), remain dormant or begin
proliferating. Cells that begin proliferating, however, are not
necessarily destined to become large vascularized meta-
stases, as a large proportion of micrometastases either die off
or become dormant. Although cells that commence prolifera-
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Figure 2
Upon arriving in a secondary site the majority of metastatic cells extravasate and proceed to one of three possible fates: they can undergo cell
death (apoptosis), remain dormant or begin proliferating. In order to form a large, vascularized and clinically relevant metastatic tumour (C), a single
cell must begin and continue proliferating as well as acquire a vasculature by angiogenesis. Dormant single cells (A) and micrometastases (B) are
possible sources of recurrent cancer.ting and continue growing as metastases may be of primary
concern clinically, dormant single cells and micrometastases
also have clinical implications, as they can be a source of
cells responsible for recurrence.
While dormancy may occur at both the single cell and
micrometastasis stages of metastasis formation, these two
types of dormancy differ in several significant ways, including
the mechanisms controlling their dormancy, their proliferation
status, and likely their response to treatment. Solitary cell
dormancy is a quiescent state defined by lack of proliferation
and apoptosis (currently as assessed by histology) and
retention of inert fluorescent or other markers that are diluted
and unobservable after a few cycles of cell division [15,19,21].
This indicates solitary cell dormancy is due to cell cycle arrest.
In contrast, micrometastasis dormancy is characterized not by
the absence of proliferation and apoptosis, but by the balance
of the two such that the tumour does not increase in size [22].
Although these two modes of dormancy are thus distinct, one
parallel between the two types of metastatic dormancy is the
limited number of experimental models, and difficulty imaging
those available in vivo complicates their study.
Experimental models and possible
mechanisms of metastatic dormancy
Several inherent difficulties have restricted, and continue to
restrict, the study of metastatic dormancy in vivo. The primary
impediments are the limited number of metastasis dormancy
models and the technical difficulty of imaging a single cell or
small group of cells in vivo, particularly in internal organs.
Solitary cell and micrometastasis models of tumour
dormancy, as well as the techniques used to study them and
possible molecular mechanisms that have been revealed by
these experiments, have recently been reviewed [16,28,29].
A commonality between both types of metastatic dormancy is
that when studying metastasis experimentally, cell lines are
classified as metastatic due to their ability to proliferate
shortly after arrival in a secondary tissue. This has had a
significant role in limiting the number of dormancy models
available, because the rapid growth of a small proportion of
proliferating cells to form metastases minimizes the time in
which dormant cells and micrometastases can be observed
and studied. This situation has been identified in several cell
lines in which solitary cells and micrometastases are
observed in the same tissue in which metastases are actively
growing [18-21,24]. It is also likely that by selecting for cell
lines that grow soon after injection, cell lines that may be
ideal for studying dormancy have been misclassified as non-
metastatic. A similar situation was clearly demonstrated by
Naumov and colleagues [30] in experiments in which many
“non-tumourigenic” cell lines were actually able to form
tumours, but only after significant periods of time outside the
range of observation for most in vivo experiments.
Ideally, models of metastatic dormancy would consist of a
population of cells that would become dormant, either as
single cells or micrometastases, upon arrival in a secondary
tissue, and emerge from dormancy after a predictable period
of time and/or in response to experimental stimuli. As breast
cancer commonly metastasizes to internal organs such as
liver, lung, bone and brain, the ability to observe dormant cells
experimentally in a realistic microenvironment is complicated
by difficulty in longitudinally imaging cells in these internal
tissues. Even in a model in which dormant cells or micro-
metastases are known to exist, locating and observing small
numbers of cells in vivo is technically challenging [31].
Advances in cellular imaging techniques, such as brighter
and dual-fluorescence cell markers, inorganic labels that do
not photo-bleach and longitudinal single cell imaging by MRI,
are slowly facilitating this process [21,32-35]. In conse-
quence, the great majority of what is known about metastatic
dormancy in vivo has been determined by histology, or by
using chick chorioallantoic membrane models [36-39] or
models that use superficial anatomic sites (for example,
vitreous fluid/cornea, subcutaneous, and so on), which are
much easier to image than internal organs.
As may be expected due to the challenges facing in vivo
studies, the exact mechanisms controlling metastatic
dormancy have not been fully elucidated. However, many
molecules and pathways believed to be involved in solitary cell
and micrometastasis dormancy have been identified. The
molecules and pathways implicated in solitary cell dormancy
are not, surprisingly, molecules that are capable of controlling
cell cycle, either directly or through signalling pathways. These
include p21, p27, Myc, uPAR, ERK and p38 [39-43]. In
contrast, micrometastasis dormancy is thought to be regulated
by the balance of pro-angiogenic proteins and angiogenic
inhibitors produced by both tumour and stromal cells
[29,30,44]. The mechanistic differences between the two
types of metastatic dormancy are significant, as most
treatments will likely have vastly different effects on these two
distinct cell populations. This difference must, therefore, be
kept in mind when considering the impact of treatment on
dormancy and recurrence. Additionally, there is evidence to
suggest that one mechanism of action for the class of
metastasis suppressor genes is through inhibition of growth of
tumour cells at metastatic sites, perhaps through induction of
cellular or micrometastatic dormancy (see [31] for a review).
Clinical implications
When considering what we understand to date regarding
tumour dormancy, most publications have focused on the
development of delayed systemic metastases as evidence for
tumour cell dormancy. However, given that the majority of
patients are currently treated by breast-conserving surgery
(or lumpectomy) and or sentinel lymph node sampling (rather
than full axillary node dissection for lymph node negative
cancers), delayed locoregional metastases should also be
considered to give evidence for tumour dormancy within the
breast or lymphatic parenchyma. Although most patients
considered high risk for early recurrence and death (locally
Breast Cancer Research    Vol 9 No 3 Brackstone et al.
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distant metastases at diagnosis) die within the first two to
four years (which likely represent the first peak identified by
Demicheli [7]; Figure 1), patients with early breast cancer can
be as much at risk of distant disease as they are of delayed
locoregional disease [1].
There has been speculation that dormant tumour cells may
represent cancer stem cells [17], which lack the cell receptor
differentiation of breast cells, that is, they do not express
estrogen or progesterone cell surface receptors and, as
such, would be insensitive to hormonal therapy. They likely
would also be resistant to cytotoxic chemotherapy due to
their inherent drug resistance. Current findings that the
majority of patients with hormonally sensitive tumours (which
represents the majority of breast cancers diagnosed) recur
following the completion of five years of hormonal therapy
would suggest that changes in either the tumour cell or host
environment do not favour recurrence until the completion of
treatment. Perhaps more can be understood about this when
we obtain long-term follow-up data from the National Cancer
Institute of Canada Clinical Trials Group MA.17 study looking
at extended adjuvant treatment for a minimum of ten years
following surgery [13].
The development of metastatic disease is felt to proceed in
an ordered fashion, arising from primary tumour cells having
developed metastatic potential, with locoregional then distant
metastases in sequence (Figure 2). This is supported
clinically by the improvement of survival in patients treated
with locoregional radiation [14]. With this notion, it becomes
increasingly important to understand how metastatic
transformation can develop with the current treatments aimed
at locoregional control, particularly since most early breast
cancer patients with favourable phenotypic features will
undergo lumpectomy with adjuvant radiation, often without
the addition of systemic therapy. Although micrometastatic
cell clusters should be sensitive to systemic chemotherapy,
isolated dormant tumour cells and cancer stem cells in cell
cycle arrest may be resistant to such regional as well as
systemic therapies, resulting in a gradual increase in delayed
recurrences among these early breast cancers over time. This
theory is supported by Demicheli’s persistent delayed peak in
recurrence despite chemotherapy (Figure 1), as well as
delayed recurrences seen in the more recent literature
[1,2,14]. In fact, the dampening in early recurrence demon-
strated in Figure 1 due to chemotherapy may be due to the
effect of systemic chemotherapy upon disseminated non-
dormant or ‘awakened’ micrometastatic cell clusters alone
[10], with no impact upon either dormant isolated tumour
cells or cancer stem cells. According to the theory of disease
progression, one would expect dormant cells to present later
than micrometastatic cell clusters (Figure 2). Perhaps there is
a promotion of dormancy initiated by local treatments and
hormonal therapy (even though such tumour cells are
speculated to be estrogen and progesterone insensitive),
which leads to a persistent recurrence risk over the following
decade or two. The influence of radiation upon the develop-
ment of metastatic capability and on dormant cells is not
known, and there are no good pre-clinical models examining
this aspect of tumour dormancy at present.
Suggestions for future research
There has been great interest in the development of gene
microarray technology as a means by which tumour behaviour
can be predicted. For example, two competing products now
being marketed evaluate 70 and 21 gene expression profiles
in breast cancer tissue, which are said to have an ability to
predict with 80% accuracy [45,46] those tumours that will
behave as ‘high risk’ cancers, with much greater risk of
metastasis development. Additionally, these gene expression
profiles demonstrate a 25% to 30% discordance with current
phenotypic categorization of tumour risk for metastases. A
potential advantage of this diagnostic modality is that
molecular phenotypic in addition to tumour phenotypic
features could be included in the determination of metastatic
potential and potential tumour susceptibility to systemic
therapy. Critics of these gene expression profiling tools as a
method for identifying cells with metastatic potential suggest
that bulk tumour analysis will fail to identify the few cells
within the large number of non-metastatic cells, and caution
that they thus should not be used to infer molecular
mechanisms. Additionally, the gene array profiles of tumour
cells sampled at sites of distant recurrences have been
reported to be genetically more similar to the primary tumours
than they are to metastases found in other patients [47],
suggesting that the similarities identified in the gene array
profiles may highlight a patient’s germline genetic poly-
morphisms rather than genetic mutations leading to the
development of these metastases [48]. In other words, this is
felt to mean that gene profiles predicting for and allowing
metastases may indicate germline polymorphisms inherent to
the host. Studies by Hunter [48] thus raise the possibility that
individuals may be differentially susceptible to support or fail
to support metastatic growth, depending on their germline
make-up. Whether this concept can be applied to an under-
standing of factors that contribute to metastatic dormancy
and probability of tumour cells re-awakening remains to be
assessed.
Mechanisms that allow for, or lead to, tumour dormancy
awakening remain very poorly understood and require further
study. Questions raised by the data emerging in the setting of
current clinical and biological behaviour of breast cancer
include: what are the factors that can promote awakening of
dormant cells - host immune factors, host polymorphisms, or
other features? Is it possible to predictably influence
dormancy by hormonal or other manipulations? What impact
does radiation have upon dormant tumour cells in breast
cancer? Will genotyping of tumours result in clinical benefit
for patients and lead to further understanding of patient or
tumour features that indicate high risk of harbouring dormant
Available online http://breast-cancer-research.com/content/9/3/208
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of questions, improved experimental models coupled with
longer-term follow-up on patients treated by current therapies
and the effects of these therapies on late recurrences are
needed.
Conclusion
Here we have reviewed clinical concepts related to tumour
dormancy in breast cancer, and have considered the potential
effects of modern therapies on long-term dormancy and late
recurrences. We also have discussed concepts of tumour
dormancy derived from pre-clinical research models of
dormancy in breast cancer. Proposed areas of future
research include the need to expand our understanding of
clinical tumour dormancy of breast cancer in the era of
locoregional radiation, prolonged hormonal therapy and
genetic profiling, as well as the need for more and better
experimental models with which to study tumour dormancy,
the mechanisms responsible and the factors that may be able
to influence either the maintenance of dormancy on the re-
awakening of dormant tumour cells.
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